胃癌组织中NF-κB、PD-1、PD-L1的表达及其临床意义

doi:10.3760/cma.j.issn.1007-1245.2024.15.011

摘要/Abstract

摘要：

目的　探讨胃癌组织中核转录因子-κB（nuclear factor kappa B，NF-κB）、程序性细胞死亡蛋白-1（programmed cell death protein-1，PD-1）、程序性细胞死亡蛋白配体-1（programmed cell death protein ligand 1，PD-L1）的表达及其临床意义。方法　选择2021年1月至2023年12月于南阳市第一人民医院治疗的62例胃癌患者手术切除后组织标本及癌旁正常组织标本分别作为胃癌组及癌旁组。62例患者中，男39例，女23例，年龄（61.86±2.31）岁，肿瘤长径（4.92±0.53）cm。采用免疫组织化学染色法检测NF-κB、PD-1、PD-L1表达情况。比较两组NF-κB、PD-1、PD-L1表达阳性率，分析其与胃癌临床病理特征的关系。采用χ²检验。结果　胃癌组NF-κB、PD-1、PD-L1表达阳性率高于癌旁组［83.87%（52/62）比33.87%（21/62）、75.81%（47/62）比30.65%（19/62）、80.65%（50/62）比40.32%（25/62）］，差异均有统计学意义（χ²=32.008、25.396、21.088，均P＜0.05）；肌层及浆膜层浸润、有淋巴结转移及Ⅲ+Ⅳ期患者NF-κB表达阳性率高于黏膜及黏膜下层浸润、无淋巴结转移及Ⅰ+Ⅱ期患者［92.68%（38/41）比66.67%（14/21）、94.74（36/38）比66.67%（16/24）、92.31%（36/39）比69.57%（16/23）］，差异均有统计学意义（χ²=5.158、6.619、3.978，均P<0.05）；肌层及浆膜层浸润、有淋巴结转移及Ⅲ+Ⅳ期患者PD-1表达阳性率高于黏膜及黏膜下层浸润、无淋巴结转移及Ⅰ+Ⅱ期患者［85.37%（35/41）比57.14%（14/21）、89.47%（34/38）比54.17%（13/24）、89.74%（35/39）比52.17%（12/23）］，差异均有统计学意义（χ²=6.031、9.998、11.135，均P<0.05）；低分化、肌层及浆膜层浸润、有淋巴结转移及Ⅲ+Ⅳ期患者PD-L1表达阳性率高于高中分化、黏膜及黏膜下层浸润、无淋巴结转移及Ⅰ+Ⅱ期患者［96.00%（24/25）比70.27%（26/37）、90.24%（37/41）比61.90%（13/21）、92.11%（35/38）比62.50%（15/24）、94.87%（37/39）比56.52%（13/23）］，差异均有统计学意义（χ²=4.787、5.445、6.472、11.286，均P<0.05）。结论　胃癌组织中NF-κB、PD-1、PD-L1表达阳性率升高，且NF-κB、PD-1表达与胃癌浸润深度、淋巴结转移及TNM分期有关，PD-L1表达与胃癌分化程度、浸润深度、淋巴结转移及TNM分期有关。

关键词:

胃癌, 临床病理特征, 核转录因子-κB, 程序性细胞死亡蛋白-1, 程序性细胞死亡蛋白配体1

Abstract:

Objective　To explore the expressions of nuclear factor kappa B (NF-κB), programmed cell death protein-1 (PD-1), and programmed cell death protein ligand 1 (PD-L1) in gastric cancer and their clinical significance. Methods　The specimens of the cancer tissue and paracancer tissue of 62 patients with gastric cancer treated in Nanyang First People's Hospital from January 2021 to December 2023 were selected as a gastric cancer group and a paracancer group. Among the 62 patients, there were 39 males and 23 females; they were (61.86±2.31) years old; the biggest tumor diameter was (4.92±0.53) cm. The expressions of NF-κB, PD-1, and PD-L1 were detected by immunohistochemical staining; their positive expression rates were compared between the two groups; their relationship with clinicopathological features was analyzed. χ² test was used. Results　The positive expression rates of NF-κB, PD-1, and PD-L1 in the gastric cancer group were higher than those in the paracancer group [83.87% (52/62) vs. 33.87% (21/62), 75.81% (47/62) vs. 30.65% (19/62), and 80.65% (50/62) vs. 40.32% (25/62)], with statistical differences (χ²=32.008, 25.396, and 21.088; all P<0.05). The positive expression rates of NF-κB in the patients with muscle and serosal infiltration, lymph node metastasis, and stage Ⅲ+Ⅳ were higher than those in the patients with mucosa and submucosa infiltration, no lymph node metastasis, and stage Ⅰ+Ⅱ [92.68% (38/41) vs. 66.67% (14/21), 94.74 (36/38) vs. 66.67% (16/24), and 92.31% (36/39) vs. 69.57% (16/23)], with statistical differences (χ²=5.158, 6.619, and 3.978; all P<0.05). The positive expression rates of PD-1 in the patients with muscle and serosal infiltration, lymph node metastasis, and stage Ⅲ+Ⅳ were higher than those in the patients with mucosa and submucosa infiltration, no lymph node metastasis, and stage Ⅰ+Ⅱ [85.37% (35/41) vs. 57.14% (14/21), 89.47% (34/38) vs. 54.17% (13/24), and 89.74% (35/39) vs. 52.17% (12/23)], with statistical differences (χ²=6.031, 9.998, and 11.135; all P<0.05). The positive expression rates of PD-L1 in the patients with low differentiation, muscle and serosal infiltration, lymph node metastasis, and stage Ⅲ+Ⅳ were higher than those in the patients with high differentiation, mucosa and submucosa infiltration, no lymph node metastasis, and stage Ⅰ+Ⅱ [96.00% (24/25) vs. 70.27% (26/37), 90.24% (37/41) vs. 61.90% (13/21), 92.11% (35/38) vs. 62.50% (15/24), and 94.87% (37/39) vs. 56.52% (13/23)], with statistical differences (χ²=4.787, 5.445, 6.472, and 11.286; all P<0.05). Conclusions　The positive expressions of NF-κB, PD-1, and PD-L1 in gastric cancer are increased. The expressions of NF-κB and PD-1 are related to the depth of gastric cancer invasion, lymph node metastasis, and TNM stage. The expression of PD-L1 is related to the degree of differentiation, depth of invasion, lymph node metastasis, and TNM stage of gastric cancer.

Key words:

Gastric cancer, Clinicopathological features, Nuclear transcription factor-κB, Programmed cell death protein-1, Programmed cell death protein ligand 1

张丽柯徐全晓李媛媛杨卫.

胃癌组织中NF-κB、PD-1、PD-L1的表达及其临床意义 [J]. 国际医药卫生导报, 2024, 30(15): 2519-2523.

Zhang Like, Xu Quanxiao, Li Yuanyuan, Yang Wei.

Expressions of NF-κB, PD-1, and PD-L1 in gastric cancer and their clinical significance [J]. International Medicine and Health Guidance News, 2024, 30(15): 2519-2523.

参考文献

[1] 农苡妍,高祥姿,马旭彦,等.双重超声造影联合血清胃蛋白酶原在早期胃癌诊断中的应用价值[J].中华超声影像学杂志,2023,32(10):858-863. DOI:10.3760/cma.j.cn131148-20230308-00137.
[2] 夏楠,高毓,周福祥.富含CXCL13+CD8+T细胞胃癌患者具有不良临床预后和免疫逃逸[J].中华医学杂志,2022,102(12):888. DOI: 10.3760/cma.j.issn.0376-2491. 2022.12.103.
[3] 缪小兵,沈蓉,张邢松,等.RNAscope原位杂交技术在胃癌PD-1、PD-L1表达分析中的应用[J].临床与实验病理学杂志, 2022, 38(3): 337-339, 343. DOI:10.13315/j.cnki.cjcep.2022.03.018.
[4] Wang Z, Kang W, Li O, et al. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing [J].Acta Pharm Sin B, 2021, 11(3): 694-707. DOI: 10.1016/j.apsb.2020.11.005.
[5] 付刚,王晓敏,曹波,等.PD-1和PD-L1在透明细胞肾细胞癌患者外周血和肿瘤组织中的表达及相关性[J].诊断病理学杂志, 2020, 27(10): 719-722. DOI: 10.3969/j.issn.1007-8096.2020.10.008.
[6] 冯晓洁,雷霏,刘宏伟,等.血清MMP-2、NF-κB水平对进展期胃癌患者新辅助化疗效果的影响及评估价值[J].广西医学,2023,45(10):1143-1147. DOI:10.11675/j.issn.0253- 4304. 2023.10.02.
[7] Chen B, Liu X, Yu P, et al. pylori-induced NF-κB-PIEZO1-YAP1-CTGF axis drives gastric cancer progression and cancer-associated fibroblast-mediated tumour microenvironment remodeling [J]. Clin Transl Med, 2023, 13(11): e1481. DOI:10.1002/ctm2.1481.
[8] 李雪,莫翠毅,陈嘉嘉,等.早期胃癌肿瘤浸润深度与癌组织PD-L1、Arg-1表达的关系[J].临床和实验医学杂志, 2023, 22(1): 19-23. DOI: 10.3969/j.issn.1671-4695. 2023.01.006.
[9] 杨洁, 彭志红, 吴宏博.miR-93表达与内镜黏膜下剥离术治疗老年早期胃癌预后的关系及其靶向抑癌基因的生物信息学分析[J].中国内镜杂志, 2020, 26(9): 11-18. DOI:10.3969/j.issn.1007-1989.2020.09.003.
[10] 刘立, 盖金娜, 尹作文, 等. 趋化因子CXCL5调控NF-κB与Wnt/β-catenin信号通路抑制肿瘤免疫促进胃癌的机制研究[J].肿瘤防治研究, 2020, 47(5): 340-345. DOI: 10.3971/j.issn.1000-8578.2020.19.1156.
[11] 王洋,邹新梅,潘琴梅,等.Hp感染性胃癌患者外周血单核细胞TLR4/MyD88/NF-κB信号通路的变化及其临床意义[J].世界华人消化杂志,2021,29(6):319-324. DOI:10.11569/wcjd.v29.i6.319.
[12] 曹一凡,张如通,苟雅雯,等.PHF5A通过NF-κB通路影响胃癌细胞MGC803的增殖和迁移[J].安徽医科大学学报, 2020, 55(8): 1198-1203.DOI:10.19405/j.cnki.issn1000- 1492. 2020.08.010.
[13] 杨波, 杨涛, 杨东霞, 等.NF-κB Apaf-1蛋白在胃癌组织中的表达及意义[J].河北医学, 2022, 28(5): 766-770. DOI: 10.3969/j.issn.1006-6233.2022.05.014.
[14] 蒋海涛, 陈银, 李福青, 等.Notch3、LGR5及NF-κB在大肠腺癌组织中的表达及意义[J].西部医学, 2023, 35(7): 982-986. DOI: 10.3969/j.issn.1672-3511.2023.07.008.
[15] 宫爱杰, 米建强.COX-2、P-Akt和NF-κB在胃癌和癌前病变中的表达及临床意义[J].四川医学, 2023, 44(7): 712-717. DOI:10.16252/j.cnki.issn1004-0501-2023. 07.008.
[16] Mirzaei S, Saghari S, Bassiri F, et al.NF-κB as a regulator of cancer metastasis and therapy response: A focus on epithelial-mesenchymal transition[J].J Cell Physiol, 2022, 237(7): 2770-2795. DOI: 10.1002/jcp.30759.
[17] 张蓝方,张明娟,许进秀,等.PD-1/PD-L1通路、Th17和Tregs细胞在肿瘤免疫中的作用[J].现代肿瘤医学, 2023, 31(18): 3519-3523. DOI: 10.3969/j.issn.1672-4992. 2023.18.035.
[18] 陈瑛,章汝楠,李楠,等.EB病毒相关性胃癌PD-1和PD-L1信号通路表达水平及意义[J].中华医院感染学杂志,2022,32(17):2642-2646. DOI: 10.11816/cn.ni.2022-211818.
[19] 左学良,陈志强,董润雨,等.联合检测LDHA和PD-L1在晚期胃癌PD-1抑制剂疗效预测及预后评估中的价值[J].中国癌症杂志,2023,33(5):460-468. DOI: 10.19401/j.cnki.1007- 3639.2023.05.006.
[20] 刘文静,李侠,王崇,等.PD-1、PD-L1与炎症标志物在胃癌患者中的相关性[J].分子诊断与治疗杂志,2022,14(5):883-886. DOI: 10.3969/j.issn.1674-6929.2022.05.041.
[21] 郭晓宇,米建强,米优嘉,等.胃癌组织中PD-1、PD-L1表达变化及其意义[J].山东医药,2020,60(12):50-52. DOI: 10.3969/j.issn.1002-266X.2020.12.012.
[22] 傅文兰,李丹,周云泷.PD-1/PD-L1抗体对胃癌的预后生存及不良反应的影响[J].现代消化及介入诊疗, 2023, 28(10): 1281-1284. DOI: 10.3969/j.issn.1672-2159. 2023.10.017.
[23] 彭进,王伟宁,罗文,等.胃癌患者幽门螺旋杆菌感染程度与PD-1、PD-L1表达水平的相关性[J].中国临床研究, 2022, 35(11): 1565-1569. DOI: 10.13429/j.cnki.cjcr.2022. 11.017.
[24] 韩艳丽, 邹俊伟, 汪俊茹.MMR及PD-L1在胃癌中的病理学表达特征及相关性研究[J].皖南医学院学报, 2023, 42(3): 236-239. DOI: 10.3969/j.issn.1002-0217.2023.03.009.
[25] 徐小玉,李雪华,韩海娥.结肠癌组织中PD-1、PD-L1表达及临床意义[J].国际医药卫生导报, 2020, 26(6): 815-819. DOI: 10.3760/cma.j.issn.1007-1245.2020.06.022.